NCT04747392View on ClinicalTrials.gov

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

November 11, 2020

Conditions
Postmenopausal Osteoporosis
Interventions
BIOLOGICAL

SAL001

administrated once by subcutaneous injection

BIOLOGICAL

FORSTEO

administrated once by subcutaneous injection

Trial Locations (1)

Unknown

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04747392 - Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults | Biotech Hunter | Biotech Hunter